SCHEMBL31367533

SCHEMBL31367533

Clc1ccccc1-c1cc(-c2ccccc2)c2nc(-c3ccccc3)cn2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A3 P47895 7/20 0.57
ALDH1A2 O94788 4/20 0.57
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
MAPT P10636 2/20 0.52
NFKB1 P19838 1/20 0.52
NFKB2 Q00653 1/20 0.52
RELA Q04206 1/20 0.52
ADORA1 P30542 4/20 0.49
ADORA2A P29274 3/20 0.49
CYP2A6 P11509 1/20 0.49
ALDH1A1 P00352 4/20 0.43
TP53 P04637 2/20 0.42
HPGD P15428 2/20 0.42
KDM4E B2RXH2 1/20 0.42
TSHR P16473 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PDCD1 Q15116 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31367413 0.89 ALDH1A3 (0.50) ALDH1A3ALDH1A2NPC1RAB9ASMN1; SMN2
SCHEMBL31367421 0.89 ALDH1A3 (0.54) ALDH1A3ALDH1A2NPC1RAB9ASMN1; SMN2
SCHEMBL31367607 0.85 ALDH1A3 (0.63) ALDH1A3ALDH1A2NPC1RAB9ASMN1; SMN2
SCHEMBL31367459 0.83 ALDH1A3 (0.57) ALDH1A3ALDH1A2NPC1RAB9ASMN1; SMN2
SCHEMBL31367491 0.83 ALDH1A3 (0.57) ALDH1A3ALDH1A2NPC1RAB9ASMN1; SMN2
SCHEMBL31367579 0.83 ALDH1A3 (0.57) ALDH1A3ALDH1A2NPC1RAB9ASMN1; SMN2
SCHEMBL31367430 0.83 ALDH1A3 (0.68) ALDH1A3ALDH1A2NPC1RAB9ASMN1; SMN2
SCHEMBL31367483 0.83 ALDH1A3 (0.68) ALDH1A3ALDH1A2NPC1RAB9ASMN1; SMN2
SCHEMBL31367603 0.83 ALDH1A3 (0.57) ALDH1A3ALDH1A2NPC1RAB9ASMN1; SMN2
SCHEMBL31367512 0.83 ALDH1A3 (0.68) ALDH1A3ALDH1A2NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735442-A1 IMIDAZO[1,2-alpha]PYRIDINE COMPOUNDS FOR USE IN TREATING CANCER AND INFLAMMATORY DISEASES AND METHODS TO PREPARE SAID COMPOUNDS Theranib Inc. (CA) 2026-05-06 EP claimed
US-20250011322-A1 MEDICAL COMPOUND FOR THE INHIBITION OF ALDEHYDE DEHYDROGENASE SUBTYPE 1A THERANIB INC. (CA) 2025-01-09 US claimed
EP-4735442-A1 IMIDAZO[1,2-alpha]PYRIDINE COMPOUNDS FOR USE IN TREATING CANCER AND INFLAMMATORY DISEASES AND METHODS TO PREPARE SAID COMPOUNDS Theranib Inc. (CA) 2026-05-06 EP disclosed
US-20250011322-A1 MEDICAL COMPOUND FOR THE INHIBITION OF ALDEHYDE DEHYDROGENASE SUBTYPE 1A THERANIB INC. (CA) 2025-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011322-A1 MEDICAL COMPOUND FOR THE INHIBITION OF ALDEHYDE DEHYDROGENASE SUBTYPE 1A ALDH2, ALDH3A1, ALDH1A1 ALDH1A3 8/4885ALDH1A2 4/4885NPC1 1136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.